Physician profile
Frank E Fine
NPI 1700981016
$12,553.97
in general payments reported to CMS, 2019-2025
40 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $2,187 · 2021: $2,443 · 2022: $2,277 · 2023: $1,471 · 2024: $1,473 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,949.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Scilex Pharmaceuticals INC. | $1,429.23 | 2019-2024 | Ztlido |
| Glaxosmithkline, LLC. | $851.68 | 2019-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $769.16 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $766.92 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $672.30 | 2019-2022 | |
| Pfizer INC. | $583.58 | 2019-2025 | |
| Electronic Waveform Lab, INC. | $488.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $398.54 | 2019-2024 | Eliquis |
| Forte Bio-Pharma LLC | $390.43 | 2019-2024 | Prolate, Nalocet |
| Lundbeck LLC | $371.17 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $366.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $319.91 | 2020-2022 | |
| Almatica Pharma LLC | $292.34 | 2021-2023 | Gralise, Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $280.21 | 2019-2023 | Trintellix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.